

## Diabetes guideline update Committee meeting

**Date:** 5/9/20

**Location:** Zoom

**Minutes:** Final

### Committee members present:

|                          |                         |
|--------------------------|-------------------------|
| Ibrahim Abubakar (Chair) | Present for items 1 - 7 |
| Sarah Ali                | Present for items 1 - 7 |
| Jonathan Webber          | Present for items 1 - 7 |
| Soon Song                | Present for items 1 - 7 |
| Anne Dornhorst           | Present for items 1 - 7 |
| Sharon McCarthy          | Present for items 1 - 7 |
| Nicola Milne             | Present for items 1 - 7 |
| Chirag Bakhai            | Present for items 1 - 7 |
| Dorothy Frizelle         | Present for items 1 - 7 |
| Natasha Jacques          | Present for items 1 - 7 |
| Sallianne Kavanagh       | Present for items 1 - 7 |
| Sian Rilstone            | Present for items 1 - 7 |
| Hugh Gallagher           | Present for items 1 - 7 |
| Daniel Newman            | Present for items 1 - 7 |
| Katie Young              | Present for items 1 - 2 |
| Rohan McMillan           | Present for items 1 - 7 |

### In attendance:

|                    |                                      |                         |
|--------------------|--------------------------------------|-------------------------|
| Rupert Franklin    | Guideline Commissioning Manager      | Present for items 1 - 7 |
| Kusal Lokuge       | Technical Analyst (Health Economics) | Present for items 1 - 7 |
| Caroline Mulvihill | Technical Adviser                    | Present for items 1 - 7 |
| Anneka Patel       | Project Manager                      | Present for items 1 - 7 |
| Gabriel Rogers     | Technical Adviser (Health Economics) | Present for items 1 - 7 |
| Shreya Shukla      | Technical Analyst                    | Present for items 1 - 7 |

### Observers:

|                   |                          |
|-------------------|--------------------------|
| Jacqueline Durkin | Administrator            |
| Thomas Jones      | Technical Analyst (HE)   |
| David Nicholls    | Information Specialist   |
| Marie Harrisingh  | Senior Technical Analyst |

|                   |                           |
|-------------------|---------------------------|
| <b>Apologies:</b> |                           |
| Augustin Brooks   | Committee member          |
| Neel Basudev      | Committee member          |
| Susan Spiers      | NICE – Associate director |

|  |
|--|
| <b>1. Welcome and objectives for the meeting</b>   |
| <p>The Chair welcomed the Committee members and attendees to GCOM4 on Diabetes.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: Clinical evidence and NMA/HE economic modelling of Insulin therapy. As such, the Chair highlighted that only topic specific experts had been invited to attend this meeting.</p> |
| <b>Introductions</b>   |
| <b>1. Confirmation of matter under discussion, and declarations of interest (DoI's)</b>  |
| <p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Insulin therapy.</p> <p>The Chair asked everyone to verbally declare any interests. Please refer to the published DOI registry.</p> <p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in this meeting.</p>                 |
| <b>2. In adults with type 1 diabetes, what are the most effective long-acting insulins (detemir versus degludec versus glargine versus NPH) and frequency of administration for optimal diabetic control? Presentation of clinical evidence</b>  |
| <p>The Chair introduced Shreya Shukla, Technical Analyst, who gave an overview of the clinical evidence in this area. The committee asked questions and answered queries from the technical team on this area.</p>   |
| <b>3. In adults with type 1 diabetes, what are the most effective long-acting</b>  |

***insulins (detemir versus degludec versus glargine versus NPH) and frequency of administration for optimal diabetic control? NMA discussion***

The Chair introduced Shreya Shukla, Technical Analyst, who gave an introduction of the NMA work for this area. The committee answered queries from the technical team on this area, including which outcomes to use for the NMA.

***4. In adults with type 1 diabetes, what are the most effective long-acting insulins (detemir versus degludec versus glargine versus NPH) and frequency of administration for optimal diabetic control? HE – results of systematic review***

The Chair introduced Kusal Lokuge, Technical Analyst (HE) who presented the results of the health economic systematic review.

***5. In adults with type 1 diabetes, what are the most effective long-acting insulins (detemir versus degludec versus glargine versus NPH) and frequency of administration for optimal diabetic control? HE – initial modelling discussion***

The Chair introduced Gabriel Rogers, Technical Adviser (HE) and Kusal Lokuge, Technical Analyst (HE) who facilitated an initial HE modelling discussion with the committee.

**6. AOB**

There was no other business noted.

**7. Summary and next steps**

Anneka Patel, Project Manager, advised that the next committee meeting would be on 5<sup>th</sup> November 2020, with the whole committee, to discuss public consultation comments for CGM in pregnancy and DKA areas.

**Date of next meeting:** Thursday, 5<sup>th</sup> November at 10am – 3pm

**Location of next meeting:** Zoom